Cargando…

Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody

Triple-negative breast cancer (TNBC) is an aggressive disease with poor prognosis and limited therapeutic options. Recent advances in the immunotherapy field have enabled the development of new treatment strategies, among which the use of bispecific antibodies (BsAbs), able to redirect T cells again...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martini, Silvia, Figini, Mariangela, Croce, Aurora, Frigerio, Barbara, Pennati, Marzia, Gianni, Alessandro Massimo, De Marco, Cinzia, Daidone, Maria Grazia, Argueta, Christian, Landesman, Yosef, Zaffaroni, Nadia, Satta, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599683/ https://www.ncbi.nlm.nih.gov/pubmed/33023194 http://dx.doi.org/10.3390/cells9102231

Ejemplares similares

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
por: Satta, Alessandro, et al.
Publicado: (2019)

miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer
por: Martini, Silvia, et al.
Publicado: (2021)

N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death
por: Dufour, Florent, et al.
Publicado: (2017)

TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes
por: Staniek, Julian, et al.
Publicado: (2019)

Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells
por: Rizzo, Andrea, et al.
Publicado: (2021)

N-glycosylation of mouse TRAIL-R restrains TRAIL-induced apoptosis
por: Estornes, Yann, et al.
Publicado: (2018)

Synergistic antitumor effects of circularly permuted TRAIL with doxorubicin in triple-negative breast cancer: Circularly permuted TRAIL with Dox in TNBC
por: Liu, Jia, et al.
Publicado: (2023)

TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill
por: Mohr, Andrea, et al.
Publicado: (2015)

TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress
por: Dufour, Florent, et al.
Publicado: (2016)

Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family
por: Degli-Esposti, Mariapia A., et al.
Publicado: (1997)

Targeting Death Receptor TRAIL-R2 by Chalcones for TRAIL-Induced Apoptosis in Cancer Cells
por: Szliszka, Ewelina, et al.
Publicado: (2012)

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
por: Tuthill, Mark H, et al.
Publicado: (2014)

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
por: Kashyap, Trinayan, et al.
Publicado: (2018)

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death
por: Argueta, Christian, et al.
Publicado: (2018)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017)

Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
por: Trivedi, Rachana, et al.
Publicado: (2015)

Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC
por: Liu, Shuang, et al.
Publicado: (2021)

Endogenous TRAIL-R4 critically impacts apoptotic and non-apoptotic TRAIL-induced signaling in cancer cells
por: Rambow, Anna-Christina, et al.
Publicado: (2022)

Assessment of concentrations of sTRAIL ligand and its receptors sTRAIL-R1 and sTRAIL-R2 – markers monitoring the course of the extrinsic pathway of apoptosis induction: potential application in ovarian cancer diagnostics
por: Mielczarek-Palacz, Aleksandra, et al.
Publicado: (2015)

TRAIL/TRAIL Receptor System and Susceptibility to Multiple Sclerosis
por: López-Gómez, Carlos, et al.
Publicado: (2011)

TRAIL combinations: The new ‘trail’ for cancer therapy (Review)
por: REFAAT, ALAA, et al.
Publicado: (2014)

Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2
por: Bertsch, U, et al.
Publicado: (2014)

Combination of AAV-TRAIL with miR-221-Zip Therapeutic Strategy Overcomes the Resistance to TRAIL Induced Apoptosis in Liver Cancer
por: Ma, Sisi, et al.
Publicado: (2017)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
por: Mittal, Sonam, et al.
Publicado: (2023)

The Nuclear Export Inhibitor Selinexor Inhibits Hypoxia Signaling Pathways And 3D Spheroid Growth Of Cancer Cells
por: Depping, Reinhard, et al.
Publicado: (2019)

Crossed TRAILs
por: Wells, William A.
Publicado: (2002)

The white trail /
por: Dafydd, Fflur
Publicado: (2011)

The information trail
por: Berman, Carol
Publicado: (2016)

John Trail
Publicado: (1889)

Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC
por: Gundlach, Jan-Paul, et al.
Publicado: (2018)

The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells
por: Ryu, Sunhyo, et al.
Publicado: (2018)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Liu, Huicheng, et al.
Publicado: (2021)

TRAIL Induces Nuclear Translocation and Chromatin Localization of TRAIL Death Receptors
por: Mert, Ufuk, et al.
Publicado: (2019)

Specific Incremental Test for Aerobic Fitness in Trail Running: IncremenTrail
por: Doucende, Grégory, et al.
Publicado: (2022)

Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy
por: Bouralexis, S, et al.
Publicado: (2003)

miR-221 Augments TRAIL-Mediated Apoptosis in Prostate Cancer Cells by Inducing Endogenous TRAIL Expression and Targeting the Functional Repressors SOCS3 and PIK3R1
por: Krebs, Markus, et al.
Publicado: (2019)

PB2100: MANAGEMENT OF RELAPSED / REFRACTORY (R/R) B-CELL NON HODGKIN LYMPHOMA (B-NHL) WITH ANTI-CD20XCD3 BISPECIFIC ANTIBODY GLOFITAMAB. A SINGLE CENTER EXPERIENCE.
por: Giatra, C., et al.
Publicado: (2022)

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
por: Crochiere, Marsha L., et al.
Publicado: (2017)

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression
por: Matte, Isabelle, et al.
Publicado: (2014)

TRAIL mutant membrane penetrating peptide alike-MuR6-TR enhances the antitumor effects of TRAIL in pancreatic carcinoma both in vitro and in vivo
por: Sun, Lei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7q619v9evjm9rr4bgjprb7c1j3